Mice treated with anti-LAG-3 or anti-TIM-3 exhibited a more variable response to treatment, with the anti-TIM-3-treated group achieving a significant reduction in tumor burden (p = 0.0492). The gene discussed is HAVCR2; the disease is neoplasm.